Jennifer MacDermott

Mrs. Jennifer MacDermott


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Life
Verified
Journal Article
Open access
PDF file
AFAri Frenkel
Ari Frenkel
ARAlicia Rendon
Alicia Rendon
CCCarlos Alberto Chavez-Lencinas
Carlos Alberto Chavez-Lencinas
JTJuan Gómez de la Torre
Juan Gómez de la Torre
JMJennifer MacDermott
Jennifer MacDermott
Miguel Hueda-ZavaletaMiguel Hueda-Zavaleta
Miguel Hueda-Zavaleta
Background: Antimicrobial stewardship programs (ASPs) are essential in combating antimicrobial resistance (AMR); however, limited resources hinder their implementation. Arkstone, a biotechnology company, developed a machine learning (ML)-driven clinical decision support system (CDSS) to guide antimicrobial prescribing. While AI (artificial intelligence) applications are increasingly used, each model must be carefully validated. Methods: Three components of the ML system were assessed: (1) A prospective observational study tested its ability to distinguish trained from novel data using various validation techniques and BioFire molecular panel inputs. (2) An anonymous retrospective analysis of internal infectious disease lab results evaluated the recognition of novel versus trained complex datasets. (3) A prospective observational validation study reviewed clinical recommendations against standard guidelines by independent clinicians. Results: The system achieved 100% accuracy (F1 = 1) in identifying 111 unique novel data points across 1110 tests over nine training sessions. It correctly identified all 519 fully trained and 644 novel complex datasets. Among 644 clinician-trained reports, there were no major discrepancies in recommendations, with only 100 showing minor differences. Conclusions: This novel ML system demonstrated high accuracy in distinguishing trained from novel data and produced recommendations consistent with clinical guidelines. These results support its value in strengthening CDSS and ASP efforts.

20 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AFAri Frenkel
Ari Frenkel
ARAlicia Rendon
Alicia Rendon
CLCarlos Chavez Lencinas
Carlos Chavez Lencinas
JTJuan Gómez de la Torre
Juan Gómez de la Torre
JMJennifer MacDermott
Jennifer MacDermott
Miguel Hueda-ZavaletaMiguel Hueda-Zavaleta
Miguel Hueda-Zavaleta
Background: Antimicrobial stewardship programs (ASPs) are essential in combating antimicrobial resistance (AMR), however, limited resources hinder their implementation. Arkstone, a biotechnology company, developed a machine learning (ML)-driven clinical decision support system (CDSS) to guide antimicrobial prescribing. Though widely used, the model had not been previously evaluated. Methods: Three components of the ML system were assessed: (1) A prospective observational study tested its ability to distinguish trained from novel data using various validation techniques and BioFire molecular panel inputs; (2) An anonymous retrospective analysis of internal infectious disease lab results evaluated recognition of novel versus trained complex datasets; and (3) A prospective observational validation study reviewed clinical recommendations against standard guidelines by independent clinicians. Results: The system achieved 100% accuracy (F1=1) in identifying 111 unique novel data points across 1,110 tests over nine training sessions. It correctly identified all 519 fully trained and 644 novel complex datasets. Among 644 clinician-trained reports, there were no major discrepancies in recommendations, with only 100 showing minor differences. Conclusion: This novel ML system demonstrated high accuracy in distinguishing trained from novel data and produced recommendations consistent with clinical guidelines. These results support its value in strengthening CDSS and ASP efforts.